Answers are grounded in this paper and cite their sources.
In melanoma cell lines, including BRAFi-resistant cells, PD-L1 expression is variably regulated by oncogenic signaling pathways. PD-L1-exposed lymphocytes decrease MAPK signaling, which is corrected by exposure to vemurafenib, providing potential benefits of combining this drug with immunotherapies.
No takes yet. Share an insight, caveat, or question.
Atefi et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: